Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 50% · prior close shown (market closed)
Limited proprietary earnings coverage for NSRX yet — signals will sharpen as filings and earnings are ingested.
Pipeline evidence · 78d ago
NSRX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on NSRX.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Nasus Pharma Ltd (NSRX) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
NSRX's AI investment thesis
Upgrade to Premium for NSRX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$3.64
Market cap
$32.82M
Profitable
No
Revenue $1.24B
Net income
$-5.86M
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Nasus Pharma Ltd — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Nasus Pharma Ltd through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.